RxDoctor Payments Data

Amber Morton, PA

Medical · Martinsville, VANPI 1811352321

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 509 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,483 and has fallen 71.4% since, to $997 in 2025. Among medical clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,998in general payments, 2019–2025

Across 509 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Novo Nordisk$783
  • Takeda Pharmaceuticals U.S.A., Inc.$622
  • Johnson & Johnson$569
  • Gilead$529
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$8,94199%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,998 in reported general payments places this provider in the 95th percentile of 632 medical providers in Virginia.

See all medical providers in Virginia

Medicare billing

Part B allowed, 2024
$46,283
Medicare patients
275
Services billed
3,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$29,652
MounjaroTirzepatide20$21,719
EliquisApixaban26$21,453
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,066
Novolog FlexpenInsulin Aspart12$1,628
Hydroxyzine Hcl46$1,132
Alprazolam149$956
Gabapentin93$941
Albuterol Sulfate HfaAlbuterol Sulfate56$822
Doxycycline Hyclate92$766
Omeprazole100$737
Amlodipine Besylate110$570
Buspirone Hcl26$500
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst35$484
Atorvastatin Calcium61$470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$783$29,65230 claims
Lilly USA, LLCMounjaro$227$21,71920 claims
PfizerEliquis$411$21,45326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 632 medical providers in Virginia.

Other medical in Martinsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →